Abstract
In order to understand microglial senescence it is important to also understand neuroinflammation because the distinction between senescent and activated microglia is a fine one to make and not always made easily. Indeed, it is not easy to reliably identify activated microglia which is why we spend some effort here discussing intricacies associated with both acute and chronic neuroinflammation before addressing the subject of microglial senescence. The idea of microglial senescence in the context of aging-related neurodegenerative disease (NDD) pathogenesis represents a relatively recent idea that emerged largely because of the many caveats and inconsistencies found to be associated with the belief that neuroinflammation is a critical event in NDD pathogenesis. In this paper, we discuss most of these discrepancies and explain why microglial senescence can provide a better conceptual framework for understanding NDD mechanisms and for devising radically different pharmacological approaches to treatment.
Keywords: Neuroinflammation, neurodegenerative disease, microglial activation, microglial dystrophy, Alzheimer’s disease.
CNS & Neurological Disorders - Drug Targets
Title:Microglial Senescence
Volume: 12 Issue: 6
Author(s): Wolfgang J. Streit and Qing-Shan Xue
Affiliation:
Keywords: Neuroinflammation, neurodegenerative disease, microglial activation, microglial dystrophy, Alzheimer’s disease.
Abstract: In order to understand microglial senescence it is important to also understand neuroinflammation because the distinction between senescent and activated microglia is a fine one to make and not always made easily. Indeed, it is not easy to reliably identify activated microglia which is why we spend some effort here discussing intricacies associated with both acute and chronic neuroinflammation before addressing the subject of microglial senescence. The idea of microglial senescence in the context of aging-related neurodegenerative disease (NDD) pathogenesis represents a relatively recent idea that emerged largely because of the many caveats and inconsistencies found to be associated with the belief that neuroinflammation is a critical event in NDD pathogenesis. In this paper, we discuss most of these discrepancies and explain why microglial senescence can provide a better conceptual framework for understanding NDD mechanisms and for devising radically different pharmacological approaches to treatment.
Export Options
About this article
Cite this article as:
Streit J. Wolfgang and Xue Qing-Shan, Microglial Senescence, CNS & Neurological Disorders - Drug Targets 2013; 12 (6) . https://dx.doi.org/10.2174/18715273113126660176
DOI https://dx.doi.org/10.2174/18715273113126660176 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry The Leptin System: A Potential Target for Sepsis Induced Immune Suppression
Endocrine, Metabolic & Immune Disorders - Drug Targets Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs
Current Rheumatology Reviews Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transmissibility and Epidemicity of COVID-19 in India: A Case Study
Recent Advances in Anti-Infective Drug Discovery The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Xenobiotic and Non-Xenobiotic Interventions in the Microbiome Therapeutics
Current Drug Metabolism In vitro And In vivo Immunomodulating Properties of Mesenchymal Stem Cells
Recent Patents on Inflammation & Allergy Drug Discovery Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property
Recent Patents on Inflammation & Allergy Drug Discovery Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy